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Abstract
Background & aim: Mesenchymal stromal cell (MSC) infusion could be a mean to establish tolerance in solid organ recipients. The aim of this prospective, controlled, phase-1 study was to evaluate the feasibility, safety and tolerability of a single infusion of MSCs in liver transplant recipients.
Methods: Ten liver transplant recipients under standard immunosuppression received 1.5-3x10 6 /kg third-party unrelated MSCs on post-operative day 3±2, and were prospectively compared to a control group of 10 liver transplant recipients. As primary end-points, MSC infusional toxicity was evaluated, and infectious and cancerous complications were prospectively recorded until month 12 in both groups. As secondary end-points, rejection rate, month-6 graft biopsies, and peripheral blood lymphocyte phenotyping were compared.
Progressive immunosuppression weaning was attempted from month 6 to 12 in MSC recipients. Conclusions: No side effect of MSC infusion at day 3 after liver transplant could be detected, but this infusion did not promote tolerance. This study opens the way for further MSC or
Treg-based trials in liver transplant recipients.
Introduction
Liver transplantation (LT) has become the gold standard treatment of many hepatic end-stage diseases. Long-term graft and patient survivals are now common after LT, but recipients are still submitted to life-long immunosuppression, which impairs quality of life and might reduce survival by promoting cancer development or by increasing the risks for infection, kidney function impairment and cardiovascular diseases. There is therefore a need for improvement in the immunosuppressive protocols after LT. Finding a way to establish donorspecific immunological tolerance without the need for non-specific immunosuppression remains one of the major goals in transplantation medicine [1] .
Mesenchymal stromal cells (MSCs) are multipotent progenitors within the bone marrow, capable of differentiating into various cells and tissues, such as chondrocytes, osteoblasts and adipocytes [2] . MSCs can be isolated after ex vivo culture of the adherent mononuclear bone marrow cell fraction. In addition to the bone marrow, MSCs reside in the connective tissues of many organs including the liver. After ex vivo expansion, human MSCs have a fibroblasticlike morphology, and are uniformly positive for SH2, SH3, CD29, CD44, CD71, CD90, CD105, CD106, CD120a, CD124, and CD166, but are negative for common hematopoietic markers such as CD14, CD45 or CD34 [2] . Human MSCs express HLA-class I and can be induced to express HLA-class II by IFN-γ. A large number of in vitro and in vivo studies have documented the anti-inflammatory and immunoregulatory properties of MSCs on both the adaptive and innate immune system [3] , as well as a potential beneficial effect in ischemiareperfusion injury [4, 5] . Specifically, MSCs have been shown to decrease effector T-cell response while promoting the emergence of regulatory T-cells (Treg) [6] . These MSC properties suggest that they could be particularly attractive in solid organ transplantation (SOT) [7, 8] , and a consortium of European academic centres studying this subject has been created (http://www.misot.eu). A first randomized controlled trial evaluating the effects of autologous MSCs in living related kidney transplantation has been performed in China [9] . In this study, MSCs significantly correlated with fewer acute rejections, a lower risk of opportunistic infections and a better renal function at 1 month. Furthermore, fewer adverse effects were seen in the MSC groups compared to the control group [9] . Compared to other transplanted organs, the liver graft is immunologically protected, and LT recipients are considered the ideal candidates for MSC therapy and for operative tolerance trials after SOT [10] . To date there has been no published trial evaluating MSC infusion in a series of LT patients [1] .
Despite the absence of major adverse effects in the preliminary clinical trials evaluating MSC-based therapy to date [11] , clinical infusion of MSCs might theoretically be complicated by impairment of pulmonary function due to MSC embolism in the lung vasculature [12] and by a cytokine-release syndrome [13] . In addition, as MSCs are potentially immunosuppressive, another concern is the potential emergence of higher rates of opportunistic infections and induced cancers after MSC infusion in SOT recipients under immunosuppression. In a small European clinical series, MSC infusion in kidney recipients was associated with transient renal dysfunction [14] and opportunistic infections [15] . It is also possible that MSC injection promotes liver fibrosis [16] . Finally, in vitro MSC expansion and culture might generate genomic instability and chromosomal aberrations with a potential risk of MSC neoplastic transformation [17, 18] .
The aim of this study was to evaluate the feasibility, the safety and the tolerability of a single MSC infusion after LT in a first-in-man, prospective, controlled, phase-1 study. The primary endpoints were set to clinically detect potential side effects of MSC infusion, as well as the occurrence of infectious and malignant complications. As secondary end-points, the potential 
Methods

Study Design
This study was a monocentric, prospective, non-randomized, controlled, open-label trial.
Protocol inclusion and exclusion criteria are presented in Table 1 . Between March 2012 and February 2014, 10 stable and low-risk LT recipients under standard immunosuppression received 1.5-3x10 6 /kg third-party MSCs on post-operative day 3±2 (MSC group). These patients were prospectively compared to a control group of 10 LT recipients who fulfilled the study inclusion criteria, declined to receive MSCs, but accepted to be included in the trial as control patients during the same period (Control group). In addition, in patients from the MSC group who did not develop rejection and had normal graft function and month-6 graft biopsy, progressive weaning of immunosuppression was attempted (Fig 1) . Weaning of immunosuppression was not considered in the control group as it is well established that early The study was registered at ClinicalTrials.gov (protocol # NCT 01429038). Written informed consent was obtained from each MSC donor and LT patient.
Liver transplant procedures and postoperative management
The following deceased liver graft donor characteristics were prospectively collected: age, gender, donation after brain or circulatory death, Eurotransplant donor risk index (ET-DRI) [19] , cause of brain damage, terminal blood sodium level, terminal liver function tests, need for vasopressors, length of intensive care unit stay, body mass index (BMI), last 24-hour diuresis, and past cardiopulmonary resuscitation.
The LT procedures were regular deceased LT as performed in the authors' centre [20, 21] . In the MSC group, if a rejection episode had not been suspected based on the liver tests and month 6 biopsy, tacrolimus was progressively tapered from day 180 to be discontinued by day 270 in the absence of rejection (Fig 1) . A graft biopsy was performed at day 270±15 in the MSC group. MMF was administered orally from day 1 through day 270 at the dose of 500 mg bid. In the MSC group, if the patient did not develop rejection during tacrolimus withdrawal and at day 270 graft biopsy, MMF was progressively tapered and definitely discontinued by day 365 in the absence of rejection (Fig 1) . Steroid treatment consisted of administration of methylprednisolone 500 mg iv before liver graft reperfusion, followed by progressively decreasing daily doses until progressive withdrawal during month 1 (Fig 1) . 
MSC donors
Inclusion criteria for MSC donors included: unrelated to the recipient; aged >18 years; no human leucocyte antigen (HLA) matching required; fulfilling generally accepted criteria for allogeneic hematopoietic stem cell donation; and informed consent given. Exclusion criteria were: known allergy to lidocaine; any risk factor for transmissible infectious diseases; meeting generally accepted exclusion criteria for allogeneic hematopoietic stem cell donation [22] .
MSC production
MSC expansion cultures were performed and evaluated at the Laboratory of Cell and Gene Therapy (LTCG) of the University Hospital of Liege, CHU of Liege, as previously described [22, 23] . Briefly, bone marrow (BM) (30-50 mL) was collected under local anaesthesia in Cultures were maintained at 37 °C in humidified atmosphere containing 5% CO 2 for a total of about 4 weeks. The medium was replaced twice a week and, after approximately 2 weeks, the cultures were near confluence (>70%). Cells were then detached by treatment with irradiated trypsin-EDTA (Invitrogen, Merelbeke, Belgium) and replated (passaged) at a lower density to allow further expansion. A second passage was performed when the cells reached confluence again (>70%). At confluence, the cells were harvested, washed, and re-suspended using phosphate-buffered saline (PBS)-EDTA (Miltenyi Biotec, Utrecht, The Netherlands) and
Human Serum Albumin (HSA) (CDF-CAF, Brussels, Belgium). The MSCs were then frozen in a medium containing 70% PBS, 20% HSA, and 10% DMSO (WAK-Chemie, Steinbach, Germany) using standard techniques. Before infusion, the MSCs were thawed and diluted in PBS, and then injected into the patients within 60 minutes. All reagents were certified sterile, and endotoxin-free, and had been used in other clinical trials in Europe. In addition, the batch of fetal bovine serum used was selected after extensive testing, and was irradiated to ensure removal of all potential viruses. The following analyses were performed as quality controls for each MSC expansion culture: nucleated cell count on a manual cell counter, flow cytometry analysis with determination of the % cells (out of total cells) positive for CD73, CD90, and CD105, and negative for HLA-DR, CD31, CD80, CD14, CD45, CD3, and CD34; cell viability using trypan blue exclusion; microbiology testing, including standard virology, bacterial culture, and search for mycoplasma; endotoxin detection using the limulus test; and cytogenetics. MSC potency was evaluated by determining the percentage inhibition of T-cell proliferation in Mixed-Lymphocyte Reaction (MLR) essay. Finally, MSC differentiation into adipocytes, osteocytes, and chondrocytes was validated in preliminary experiments [22] .
MSC infusion
Third-party unrelated MSC infusion was performed on post-transplant day 3±2 through a central intravenous line in fully monitored, stable, conscious and extubated patients who were receiving standard LT recipient care, after liver Doppler ultrasonography confirming arterial and portal flows. MSC infusion had to be performed within 60 min of thawing, with two investigators at the patients' bedside.
Primary endpoints
-MSC infusional toxicity: the duration and volume of the MSC infusion were noted. To assess pulmonary and systemic toxicity of MSC infusion, tympanic body temperature, heart rate, mean arterial blood pressure and peripheral capillary oxygen saturation (SpO 2 ) were recorded 5 min before infusion, after 15 minutes and at the end of the MSC infusion. Clinical signs of allergy, such as skin reaction or anaphylactic shock, were also recorded.
-MSC infectious and cancerous complications: the incidence, timing and severity of any infections (bacterial, viral, fungal) and any malignant diseases were prospectively recorded until month 12 in both groups.
Secondary endpoints
Patient and graft survivals and biopsy-proven graft rejection rates were prospectively recorded in both groups until month 12. Liver graft function (bilirubin, liver enzymes, international normalized ratio (INR)), kidney function (creatinine), C-reactive protein (CRP) and tacrolimus levels were compared using standard clinical blood tests at day 7 and months 1, 3, and 6. Blood immunoglobulin levels were compared at months 1 and 6.
Liver graft biopsy and immunohistochemistry
Month-6 formalin-fixed, paraffin-embedded graft biopsies were blindly analysed by two gastrointestinal pathologists (N.B., J.S), who described fibrosis and signs of graft rejection according to the Banff criteria [24] . Paraffin-embedded sections of liver biopsy specimens (4 µm thick) underwent immunostaining using an automated immunostainer (Ventana Medical Systems, Tucson, AZ) with antibodies directed against human CD3, CD4, CD8, CD20, CD138, CD68, CD1a and FoxP3. An amplification kit (Ventana Medical Systems) and a detection system including diaminobenzidine (Ventana Medical Systems) as a chromogen were used during the automated procedure. Archival lymph node sections were used as positive controls. For negative controls, the primary antibody was omitted. The mean number of positive cells in each patient was calculated by counting these cells (original magnification, x400) in the three most cellular microscopic fields, also called hot spots.
Peripheral blood lymphocyte immunophenotyping and CD4 phenotyping
Peripheral blood mononuclear cells were phenotyped on days 30, 90 and 180 using 4-color flow cytometry after treatment with a red blood cell lyzing solution as described [25] . The 
Statistical analysis
Data are presented as median values and ranges, and the difference between groups was evaluated by the Mann-Whitney test. Proportions were analysed using Fischer's test.
Differences between repeated measures were evaluated by one-way ANOVA using the Friedman test as a post-hoc test. Survival rates were calculated with the Kaplan-Meier method and compared with the log-rank (Mantel-Cox) test. A value of P<0.05 was considered significant. Data were analysed using Prism 6.0c software for Macintosh OSX (GraphPad Software, San Diego, CA).
Results
Liver transplantation donor and recipient characteristics
No statistical difference could be detected between the MSC and control groups concerning the characteristics of both liver graft donors and recipients (supplementary material).
Primary endpoints
a) MSC infusional toxicity.
On day 3 (2-5), the 10 MSC patients received 2. No patient in either group developed life-threatening opportunistic infection or de novo cancer (including post-transplant lymphoproliferative disease) during follow-up. There was no difference in overall rates of infection between the two groups (Table 3 ). In the MSC group, two patients developed labial herpetic infections successfully treated by oral acyclovir. In addition, two MSC patients at high risk of CMV (D+, R-) developed asymptomatic CMV seroconversion under valganciclovir therapy. No patients developed CMV disease. Two patients transplanted for hepatocellular carcinoma (HCC) complicating cirrhosis had a pejorative pathology report and developed HCC recurrence: one MSC patient had a R1 LT with a HCC nodule invading the diaphragm (he died from HCC recurrence at month 10) and one control patient had an unsuspected neoplastic thrombus in a supra-hepatic vein at liver pathology (still alive at 5-year follow-up after HCC recurrence at month 23 and resection of pulmonary metastases).
Secondary Endpoints
No patient required retransplantation during the first year of follow-up. One patient from the control group died at day 16 from a hypovolemic shock induced by a fistula between the hepatic artery and the bile duct, probably due to an infected pseudoaneurysm. Six-month graft and patient survivals were 100% and 90% in the MSC and control group, respectively (NS).
One-year graft and patient survivals were 90% in both groups (NS). No patient in either group developed biopsy-proven rejection during the first 6 months of follow-up. Protocol month-6 biopsies did not demonstrate a difference between groups in the evaluation of the Banff criteria, the fibrosis score or the immunohistochemistry (Table 4 ; Fig S1 and (Table 6 ; Fig S4 in supplementary material) .
Impact of MSCs on peripheral blood CD4+ T cells (including Tregs)
The 2 groups of patients had similar counts of peripheral blood CD4+ T cells and Tconvs on days 0, 30 and 90 after transplantation (Fig 2 A-B expression) was also similar in the 2 groups of patients, as were the levels of phosphoSTAT5
in Tregs (the latter translating similar IL-2 signalling in Tregs). These combined observations suggest that a single MSC infusion had no impact on Treg count or phenotype in this study.
Immunosuppression withdrawal in the MSC group
One patient from the MSC group was excluded from immunosuppression withdrawal attempt due to HCC recurrence, but the nine others met the necessary criteria. In one patient, tacrolimus and MMF withdrawal was performed without rejection and she remained off immunosuppression for 12 months. In two patients, MMF monotherapy was achieved at month 9, but graft rejection occurred during MMF withdrawal and was successfully treated by tacrolimus reintroduction. In 6 patients, the transaminases significantly increased during tacrolimus withdrawal. In these cases, withdrawal was cancelled and liver tests normalised after increase of the tacrolimus dose.
Discussion
This phase 1, prospective, controlled study is the first to evaluate the feasibility, safety and tolerability of MSC infusion in a series of 10 LT patients under classical tacrolimus-based immunosuppression. In these patients, a post-transplantation intravenous 1.5-3x10 6 /kg MSC infusion was well tolerated, without evidence of pulmonary dysfunction or of cytokine-release syndrome. This dosing was chosen according to the authors' experiences with MSC infusion after HSC transplantation [23, 28] . These LT patients receiving MSC did not develop any evidence of impairment in vital organ functions, including the liver graft and the kidneys. In addition, they did not suffer from an increased susceptibility to infections. No de novo cancer was detected after one year of follow-up, and a HCC recurrence was observed in a patient with a very poor prognosis due to unexpected extra-hepatic HCC spread discovered during LT. For all these primary endpoints, the LT recipients who received MSCs did not react differently compared to patients in the control group. This finding is an important step in the evaluation of the potential role of MSCs in SOT recipients, and particularly after LT.
In the last decade, MSCs have been extensively studied both in vitro and in vivo. Their antiinflammatory and immunoregulatory properties [29] [3], added to potential beneficial effects on ischemia/reperfusion injury [5] , might select MSCs as a potential future therapy for SOT recipients in whom life-long immunosuppression and chronic allograft dysfunction still impair quality of life and graft survival. However, as the clinical use of MSCs is still under evaluation in preliminary trials in non-transplant patients, their potential secondary effects need to be carefully assessed in SOT recipients. Due to their size, MSCs are known to embolize within the pulmonary circulatory bed when they are infused in the peripheral or central venous circulation of mice [12] . There is therefore a theoretical risk of decreased pulmonary exchange after MSC infusion, but this complication has not been reported so far in the early phase clinical trials nor in the randomized study in living-related kidney transplantation performed in China [9] . As reported previously by our group, MSC infusion in hematopoietic stem cell transplant recipients has not been associated with any infusional toxicity [23] , nor with long-term impairment of lung function [28] . This was confirmed in the current trial, as our 10 patients receiving MSCs did not develop any sign of pulmonary dysfunction. In addition, this study did not observe any suspicion of allergy or cytokinerelease syndrome, or of any other possible complications concerning the liver graft or extrahepatic organ function. In a preliminary evaluation in 2 kidney recipients, possible toxicity of MSC infusion on kidney graft function was suggested [14] , but this "engraftment syndrome"
was not detected in our cohort of LT recipients or in any other MSC clinical trial to date.
As MSCs are immunosuppressive, SOT recipients who receive MSCs in addition to standard immunosuppression could be over-immunosuppressed and develop higher rates of opportunistic infections [26] . Again, in a small series of kidney recipients, opportunistic infections were observed after MSC treatment [15] . On the contrary, in the largest experience reported so far of MSC infusion after living-related kidney transplantation, MSC recipients developed fewer infectious complications than controls [9] . In our series, the MSC patients did not develop life-threatening infections, and no difference could be detected in comparison with the control group.
It has been suggested in in vitro experiments that MSCs might carry a potential for cancerous degeneration [17] . This potential risk has so far not been demonstrated in the preliminary MSC clinical experiences in either SOT or in non-SOT patients, and no patient in our series had developed de novo cancer after one-year follow-up. This important issue needs to be confirmed by further follow-ups of this series and by further experience in larger series.
Furthermore, in the series described here, one patient died from early HCC recurrence after a R1 LT with a very bad prognosis. The authors do not consider that HCC within Milan criteria should be excluded for further MSC trials in LT, but the possibility of an increased risk of HCC recurrence after MSC infusion cannot be excluded by this preliminary phase 1 study.
As secondary end-points, this study prospectively evaluated the possible effects of a single metabolite. Moreover, a high dose of tacrolimus seems to be toxic for MSCs, while MPA and rapamycin at a therapeutic dose just inhibit MSC proliferation [32] . Furthermore, it has been demonstrated that MPA and MSCs have a synergistic immunosuppressive effect [32] . In vivo,
MPA and MSCs also synergize to promote long-term allograft tolerance in rat heart transplantation [33] . As Tregs probably play an important role in MSC-mediated immunomodulatory effects, it is important to confirm that such a combination therapy is also favorable for Treg expansion. Hence, a recent study supported that mTOR inhibitor-based immunosuppression favours survival of Tregs after administration in a nonhuman primate model, whereas tacrolimus does not [34] .
In addition, in a phase 2 part of this study, patients from the MSC group underwent unsuccessful progressive immunosuppression weaning. Induction of operational tolerance is a major goal in SOT and particularly in LT patients [1] . Operational tolerance is a rare phenomenon after LT [18] . 
